The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per ...

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, ...